Shriya A S Kamakshi, Pawar Vaishnavi B, Paul Acsah Annie
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, 570015, Karnataka, India.
Curr Diabetes Rev. 2025;21(6):93-101. doi: 10.2174/0115733998305019240702095537.
Diabetes is a chronic medical condition that causes high glycaemic levels, leading to damage to vital organs over time. It is a common disease worldwide, affecting around 422 million individuals living in middle- and low-income countries, which make up most of the population. Unfortunately, diabetes results in 1.5 million deaths annually. Diabetic patients are at a higher risk for developing cardiovascular conditions. Diabetic heart disease constitutes multiple genres, including diabetic cardiomyopathy, coronary artery disease, and heart failure. Hypoglycaemic agents aim to prevent these metabolic issues however some of these are cardiotoxic in nature. In contrast, other hypoglycaemic agents work beyond controlling glycaemic levels with their cardioprotective properties. Given that there is an alarming increase in diabetic heart disease cases universally, we have attempted to review the existing data on the topic and the effects of hypoglycaemic drugs on heart diseases.
糖尿病是一种慢性疾病，会导致血糖水平升高，随着时间的推移会损害重要器官。它是全球常见的疾病，影响着约4.22亿生活在中低收入国家的人，这些国家占世界人口的大多数。不幸的是，糖尿病每年导致150万人死亡。糖尿病患者患心血管疾病的风险更高。糖尿病性心脏病包括多种类型，如糖尿病心肌病、冠状动脉疾病和心力衰竭。降血糖药物旨在预防这些代谢问题，但其中一些药物具有心脏毒性。相比之下，其他降血糖药物除了控制血糖水平外，还具有心脏保护作用。鉴于全球糖尿病性心脏病病例惊人地增加，我们试图回顾关于该主题的现有数据以及降血糖药物对心脏病的影响。
